Grant: Engage Grants Program
University of Alberta
$25,000.00
Evaluation of a Brain Endothelium Transmembrane Protein as a Therapeutic Target for Drug Delivery across the Blood Brain Barrier
FY 2014-15
Summary
Neurological diseases, especially cancers and infections of the brain, present a major challenge to health careproviders and drug developers alike. Most therapeutics cannot cross the blood brain barrier (BBB), whichmaintains the optimal environment for neuronal function. Current efforts in therapeutics focus on developingdrug-delivery systems and targeted drugs that allow therapeutics to cross the BBB in a safe and effectivemanner. Vertex realizes the potential of alternate and emerging drug modalities and, importantly, thepossibilities for targeted drug delivery. With the growing interest in neurological disorders in mind, Vertexaims to explore new materials that provide penetration of the BBB to its molecules, first as a tool for earlyresearch, and ultimately as a platform for approved treatments of disease. A recently identified transmembraneprotein that is selectively expressed on the brain endothelium and acts as a regulator of the transport ofmolecules across the BBB is attractive to Vertex as a potential target for delivering medicines specifically tothe brain. Identifying a peptide that binds specifically to this transmembrane protein might provide an anchorfor the development of materials for targeted drug delivery. Phage display represents one approach that hasbeen leveraged to discover molecules (peptides in this case) that recognize cell-surface receptors. Contrary totraditional phage display that allows for encoding and selection of peptide-based libraries only, the Derda groupat the University of Alberta developed methodology for chemical post-translational modification ofphage-displayed libraries to introduce unnatural moieties beyond traditional 20 amino acids. From such hybridlibraries one can rapidly identify ligands that target brain specific transmembrane proteins with high specificityand affinity. This project will focus on the identification of ligands that bind selectively to brain specifictransmembrane proteins, the functionalization of materials with these ligands, and the evaluation of thesematerials for facilitating increased uptake from the microvasculature to the brain parenchyma.
Program
Engage Grants Program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
470960-2014
Name nom
Derda, Ratmir
Department département
Chemistry
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
1
Nb partie
1
Application title
Evaluation of a Brain Endothelium Transmembrane Protein as a Therapeutic Target for Drug Delivery across the Blood Brain Barrier
Keyword
NSERC
Application summary
Neurological diseases, especially cancers and infections of the brain, present a major challenge to health careproviders and drug developers alike. Most therapeutics cannot cross the blood brain barrier (BBB), whichmaintains the optimal environment for neuronal function. Current efforts in therapeutics focus on developingdrug-delivery systems and targeted drugs that allow therapeutics to cross the BBB in a safe and effectivemanner. Vertex realizes the potential of alternate and emerging drug modalities and, importantly, thepossibilities for targeted drug delivery. With the growing interest in neurological disorders in mind, Vertexaims to explore new materials that provide penetration of the BBB to its molecules, first as a tool for earlyresearch, and ultimately as a platform for approved treatments of disease. A recently identified transmembraneprotein that is selectively expressed on the brain endothelium and acts as a regulator of the transport ofmolecules across the BBB is attractive to Vertex as a potential target for delivering medicines specifically tothe brain. Identifying a peptide that binds specifically to this transmembrane protein might provide an anchorfor the development of materials for targeted drug delivery. Phage display represents one approach that hasbeen leveraged to discover molecules (peptides in this case) that recognize cell-surface receptors. Contrary totraditional phage display that allows for encoding and selection of peptide-based libraries only, the Derda groupat the University of Alberta developed methodology for chemical post-translational modification ofphage-displayed libraries to introduce unnatural moieties beyond traditional 20 amino acids. From such hybridlibraries one can rapidly identify ligands that target brain specific transmembrane proteins with high specificityand affinity. This project will focus on the identification of ligands that bind selectively to brain specifictransmembrane proteins, the functionalization of materials with these ligands, and the evaluation of thesematerials for facilitating increased uptake from the microvasculature to the brain parenchyma.